FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3043111269> ?p ?o ?g. }

• W3043111269 abstract "Peroxisomes are subcellular organelles that are involved in various important physiological processes such as the oxidation of fatty acids and the biosynthesis of bile acids and plasmalogens. The gold standard in the diagnostic work-up for patients with peroxisomal disorders is the analysis of very long-chain fatty acid (VLCFA) levels in plasma. Alternatively, C26:0-lysophosphatidylcholine (C26:0-LPC) can be measured in dried blood spots (DBS) using liquid chromatography tandem mass spectrometry (LC-MS/MS); a fast and easy method but not yet widely used. Currently, little is known about the correlation of C26:0-LPC in DBS and C26:0-LPC in plasma, and how C26:0-LPC analysis compares to VLCFA analysis in diagnostic performance. We investigated the correlation between C26:0-LPC levels measured in DBS and plasma prepared from the same blood sample. For this analysis we included 43 controls and 38 adrenoleukodystrophy (ALD) (21 males and 17 females) and 33 Zellweger spectrum disorder (ZSD) patients. In combined control and patient samples there was a strong positive correlation between DBS and plasma C26:0-LPC (Spearman’s rank correlation coefficient of r (114) = 0.962, p < 0.001). These data show that both plasma and DBS are suitable to determine blood C26:0-LPC levels and that there is a strong correlation between C26:0-LPC levels in both matrices. Following this, we investigated how VLCFA and C26:0-LPC analysis compare in diagnostic performance for 67 controls, 26 ALD males, 19 ALD females, and 35 ZSD patients. For C26:0-LPC, all ALD and ZSD samples had C26:0-LPC levels above the upper limit of the reference range. For C26:0, one out of 67 controls had C26:0 levels above the upper reference range. For 1 out of 26 (1/26) ALD males, 1/19 ALD females and 3/35 ZSD patients, the C26:0 concentration was within the reference range. The C26:0/C22:0 ratio was within the reference range for 0/26 ALD males, 1/19 ALD females and 2/35 ZSD patients. Overall, these data demonstrate that C26:0-LPC analysis has a superior diagnostic performance compared to VLCFA analysis (C26:0 and C26:0/C22:0 ratio) in all patient groups. Based on our results we recommend implementation of C26:0-LPC analysis in DBS and/or plasma in the diagnostic work-up for peroxisomal disorders." @default.
• W3043111269 created "2020-07-23" @default.
• W3043111269 creator A5000715606 @default.
• W3043111269 creator A5002947153 @default.
• W3043111269 creator A5006093802 @default.
• W3043111269 creator A5009020389 @default.
• W3043111269 creator A5009460971 @default.
• W3043111269 creator A5009514619 @default.
• W3043111269 creator A5014167382 @default.
• W3043111269 creator A5039474873 @default.
• W3043111269 creator A5050017510 @default.
• W3043111269 creator A5057253916 @default.
• W3043111269 date "2020-07-29" @default.
• W3043111269 modified "2023-10-11" @default.
• W3043111269 title "Comparison of the Diagnostic Performance of C26:0-Lysophosphatidylcholine and Very Long-Chain Fatty Acids Analysis for Peroxisomal Disorders" @default.
• W3043111269 cites W1488851638 @default.
• W3043111269 cites W1503104627 @default.
• W3043111269 cites W1594338155 @default.
• W3043111269 cites W1767706930 @default.
• W3043111269 cites W189903418 @default.
• W3043111269 cites W1972896422 @default.
• W3043111269 cites W1973343526 @default.
• W3043111269 cites W1991664740 @default.
• W3043111269 cites W1999829596 @default.
• W3043111269 cites W2000766319 @default.
• W3043111269 cites W2005872866 @default.
• W3043111269 cites W2013004312 @default.
• W3043111269 cites W2019633271 @default.
• W3043111269 cites W2037167329 @default.
• W3043111269 cites W2056805199 @default.
• W3043111269 cites W2062319971 @default.
• W3043111269 cites W2068711980 @default.
• W3043111269 cites W2072066566 @default.
• W3043111269 cites W2090932622 @default.
• W3043111269 cites W2107786477 @default.
• W3043111269 cites W2145355107 @default.
• W3043111269 cites W2150643970 @default.
• W3043111269 cites W2154833816 @default.
• W3043111269 cites W2161968043 @default.
• W3043111269 cites W2173276475 @default.
• W3043111269 cites W2189202583 @default.
• W3043111269 cites W2338336048 @default.
• W3043111269 cites W2342942063 @default.
• W3043111269 cites W2438153122 @default.
• W3043111269 cites W2531843007 @default.
• W3043111269 cites W2560085362 @default.
• W3043111269 cites W2724305367 @default.
• W3043111269 cites W2765456519 @default.
• W3043111269 cites W2916744594 @default.
• W3043111269 cites W3036445007 @default.
• W3043111269 doi "https://doi.org/10.3389/fcell.2020.00690" @default.
• W3043111269 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7438929" @default.
• W3043111269 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32903870" @default.
• W3043111269 hasPublicationYear "2020" @default.
• W3043111269 type Work @default.
• W3043111269 sameAs 3043111269 @default.
• W3043111269 citedByCount "24" @default.
• W3043111269 countsByYear W30431112692021 @default.
• W3043111269 countsByYear W30431112692022 @default.
• W3043111269 countsByYear W30431112692023 @default.
• W3043111269 crossrefType "journal-article" @default.
• W3043111269 hasAuthorship W3043111269A5000715606 @default.
• W3043111269 hasAuthorship W3043111269A5002947153 @default.
• W3043111269 hasAuthorship W3043111269A5006093802 @default.
• W3043111269 hasAuthorship W3043111269A5009020389 @default.
• W3043111269 hasAuthorship W3043111269A5009460971 @default.
• W3043111269 hasAuthorship W3043111269A5009514619 @default.
• W3043111269 hasAuthorship W3043111269A5014167382 @default.
• W3043111269 hasAuthorship W3043111269A5039474873 @default.
• W3043111269 hasAuthorship W3043111269A5050017510 @default.
• W3043111269 hasAuthorship W3043111269A5057253916 @default.
• W3043111269 hasBestOaLocation W30431112691 @default.
• W3043111269 hasConcept C104317684 @default.
• W3043111269 hasConcept C126322002 @default.
• W3043111269 hasConcept C127078168 @default.
• W3043111269 hasConcept C134018914 @default.
• W3043111269 hasConcept C162356407 @default.
• W3043111269 hasConcept C185592680 @default.
• W3043111269 hasConcept C2776330855 @default.
• W3043111269 hasConcept C2777150068 @default.
• W3043111269 hasConcept C2777485865 @default.
• W3043111269 hasConcept C2777565452 @default.
• W3043111269 hasConcept C2778596009 @default.
• W3043111269 hasConcept C2778918659 @default.
• W3043111269 hasConcept C2781317408 @default.
• W3043111269 hasConcept C31827203 @default.
• W3043111269 hasConcept C41625074 @default.
• W3043111269 hasConcept C43617362 @default.
• W3043111269 hasConcept C543025807 @default.
• W3043111269 hasConcept C55493867 @default.
• W3043111269 hasConcept C71924100 @default.
• W3043111269 hasConcept C86803240 @default.
• W3043111269 hasConceptScore W3043111269C104317684 @default.
• W3043111269 hasConceptScore W3043111269C126322002 @default.
• W3043111269 hasConceptScore W3043111269C127078168 @default.
• W3043111269 hasConceptScore W3043111269C134018914 @default.
• W3043111269 hasConceptScore W3043111269C162356407 @default.
• W3043111269 hasConceptScore W3043111269C185592680 @default.
• W3043111269 hasConceptScore W3043111269C2776330855 @default.
• W3043111269 hasConceptScore W3043111269C2777150068 @default.

• next